.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Harvard Business School
Farmers Insurance
QuintilesIMS
McKinsey
US Army
Mallinckrodt
Covington
AstraZeneca
Moodys

Generated: July 21, 2017

DrugPatentWatch Database Preview

Alitretinoin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for alitretinoin and what is the scope of alitretinoin patent protection?

Alitretinoin
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Alitretinoin has eighteen patent family members in eleven countries.

There are two drug master file entries for alitretinoin. One supplier is listed for this compound.

Summary for Generic Name: alitretinoin

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list2
Suppliers / Packagers: see list1
Bulk Api Vendors: see list28
Clinical Trials: see list16
Patent Applications: see list9,214
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:alitretinoin at DailyMed

Pharmacology for Ingredient: alitretinoin

Ingredient-typeRetinoids
Drug ClassRetinoid
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 1999RXYesYes5,932,622► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: alitretinoin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 19995,932,622► Subscribe
Eisai Inc
PANRETIN
alitretinoin
GEL;TOPICAL020886-001Feb 2, 19997,056,954► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: alitretinoin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,056,954Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
5,968,989 Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
6,576,676 Means for the modulation of processes mediated by retinold receptors and compounds useful therefor► Subscribe
6,992,108Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor► Subscribe
6,506,917 Compounds and compositions useful for modulation of processes mediated by RXR► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alitretinoin

Country Document Number Estimated Expiration
Austria439341► Subscribe
World Intellectual Property Organization (WIPO)9311755► Subscribe
Germany69233768► Subscribe
European Patent Office0807624► Subscribe
Luxembourg90752► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALITRETINOIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/014United Kingdom► SubscribePRODUCT NAME: ALITRETINOIN; REGISTERED: UK EU/1/00/149/001 20001018
2001 00012Denmark► Subscribe
/2001Austria► SubscribePRODUCT NAME: ALITRETINOIN; REGISTRATION NO/DATE: EU/1/00/149/001 20001011
00043Netherlands► SubscribePRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
01/009Ireland► SubscribePRODUCT NAME: PANRETIN-ALITRETINOIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Farmers Insurance
Chinese Patent Office
Cerilliant
US Department of Justice
Julphar
Novartis
Accenture
UBS
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot